A review on Brain Cancer Mutations, Available Therapies, Existing Clinical Trials, and Forthcoming Brain Cancer Treatment

  • Sarmad Sheraz Jadoon State Key Laboratory of Esophageal Cancer Prevention & Treatment, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
  • Tanzeel Ahmed Bolan Medical Complex Hospital, Quetta, Pakistan.
Keywords: Brain Cancers, Brain Tumors, Glioblastoma, Prevalence, Mutations, Treatment.


Aim: This paper aims at reviewing brain cancers, types of brain cancers, and mutations.

Methodology: Multiple electronic databases were searched such as Google Scholar, PubMed, HEC digital library, Elsevier, Research Gate, and Springer for all articles published in both local and international Journals for this review. Only articles written in English language were reviewed.

Mutation: The nature of the genetic mutations that induce brain cancers, as well as previously identified medicines to treat them, such as chemotherapy, steroids, and targeted therapies, have failed to explain further study and development of various drugs still in clinical trials.

Current Therapy: Temozolomide, the combined dose of Carboplatin, Melphalan, Etoposide Phosphate, Mannitol and Sodium Thiosulfate, combined therapy of Selumetinib, Dabrafenib, and Trametinib and the use of Palbociclib in chemotherapy are therapies and drugs under clinical trials aimed at replacing the traditional methods of brain cancer management therapies.

Conclusion: This review focuses on the currently available therapies for the different types of brain cancers, available clinical trial drugs for cancer, and the future of the treatment of brain cancer. Current research on brain cancer treatment is focused on delivering therapies across the blood-brain barrier to targeted mutated brain cells.

Review Article